BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34558354)

  • 1. Novel agents for myelodysplastic syndromes.
    Xu K; Hansen E
    J Oncol Pharm Pract; 2021 Dec; 27(8):1982-1992. PubMed ID: 34558354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Thota S; Oganesian A; Azab M; Griffiths EA
    Future Oncol; 2021 Jun; 17(16):2077-2087. PubMed ID: 33709786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
    Garcia-Manero G; McCloskey J; Griffiths EA; Yee KWL; Zeidan AM; Al-Kali A; Deeg HJ; Patel PA; Sabloff M; Keating MM; Zhu N; Gabrail NY; Fazal S; Maly J; Odenike O; Kantarjian H; DeZern AE; O'Connell CL; Roboz GJ; Busque L; Buckstein R; Amin H; Randhawa J; Leber B; Shastri A; Dao KH; Oganesian A; Hao Y; Keer HN; Azab M; Savona MR
    Lancet Haematol; 2024 Jan; 11(1):e15-e26. PubMed ID: 38135371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New treatment for myelodysplastic syndromes: luspatercept and oral hypomethylating agents].
    Usuki K
    Rinsho Ketsueki; 2022; 63(9):1099-1106. PubMed ID: 36198535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
    Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
    Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine/Cedazuridine: First Approval.
    Dhillon S
    Drugs; 2020 Sep; 80(13):1373-1378. PubMed ID: 32860582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
    Kim N; Norsworthy KJ; Subramaniam S; Chen H; Manning ML; Kitabi E; Earp J; Ehrlich LA; Okusanya OO; Vallejo J; Gehrke BJ; de Claro RA; Pazdur R
    Clin Cancer Res; 2022 Aug; 28(16):3411-3416. PubMed ID: 35435961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
    Patel AA; Cahill K; Saygin C; Odenike O
    Blood Adv; 2021 Apr; 5(8):2264-2271. PubMed ID: 33904891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
    Bataller A; Montalban-Bravo G; Bazinet A; Alvarado Y; Chien K; Venugopal S; Ishizawa J; Hammond D; Swaminathan M; Sasaki K; Issa GC; Short NJ; Masarova L; Daver NG; Kadia TM; Colla S; Qiao W; Huang X; Kanagal-Shamanna R; Hendrickson S; Ravandi F; Jabbour E; Kantarjian H; Garcia-Manero G
    Lancet Haematol; 2024 Mar; 11(3):e186-e195. PubMed ID: 38316133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.
    Schiffer M; Zhao J; Johnson A; Lee J; Bewersdorf JP; Zeidan AM
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):989-1002. PubMed ID: 33853476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
    Garcia-Manero G; Griffiths EA; Steensma DP; Roboz GJ; Wells R; McCloskey J; Odenike O; DeZern AE; Yee K; Busque L; O'Connell C; Michaelis LC; Brandwein J; Kantarjian H; Oganesian A; Azab M; Savona MR
    Blood; 2020 Aug; 136(6):674-683. PubMed ID: 32285126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
    Kipp D; H Wei A
    Future Oncol; 2021 Jul; 17(20):2563-2571. PubMed ID: 33769069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
    Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
    J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Feld J; Tremblay D; Navada SC; Silverman LR
    Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of luspatercept to treat ineffective erythropoiesis.
    Kubasch AS; Fenaux P; Platzbecker U
    Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
    Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
    N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concise drug review: azacitidine and decitabine.
    Derissen EJ; Beijnen JH; Schellens JH
    Oncologist; 2013; 18(5):619-24. PubMed ID: 23671007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes.
    Tinsley-Vance SM; Davis M; Ajayi O
    J Adv Pract Oncol; 2023 Jan; 14(1):82-87. PubMed ID: 36741213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.